No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Guizhou Yibai Pharmaceutical Leads Our Trio Of Promising Penny Stocks
Guizhou Yibai Pharmaceutical Co., Ltd. 2024 Annual Results Forecast
Guizhou Yibai Pharmaceutical (600594.SH): Expected loss of 0.285 billion yuan to 0.342 billion yuan in 2024.
Gelonghui reported on January 17 that Guizhou Yibai Pharmaceutical (600594.SH) announced its annual performance forecast for 2024, expecting a net income attributable to the parent company's owners to be between -342 million yuan and -285 million yuan; this represents a loss compared to the same period last year. The company expects a net income attributable to the parent company's owners, excluding non-recurring gains and losses, to be between -348 million yuan and -290 million yuan for 2024.
Shareholders in Guizhou Yibai Pharmaceutical (SHSE:600594) Have Lost 57%, as Stock Drops 16% This Past Week
Guizhou Yibai Pharmaceutical (600594.SH): has actually repurchased 0.95% of the company's shares.
On November 28, 2023, Guizhou Yibai Pharmaceutical (600594.SH) announced that the deadline for the share repurchase has expired. The company has completed the repurchase, having repurchased a total of 7,533,500 shares through centralized bidding. The repurchased shares account for 0.95% of the company's total share capital, with the highest transaction price being 4.10 yuan per share, the lowest price being 2.89 yuan per share, and the average repurchase price being 3.32 yuan per share. The total amount paid is 24,991,703 yuan (excluding transaction commissions and other transaction costs).
The Market Doesn't Like What It Sees From Guizhou Yibai Pharmaceutical Co., Ltd.'s (SHSE:600594) Revenues Yet As Shares Tumble 25%